Will chemotherapy change the management of prostate cancer?

Gilson, Clare; Sydes, Matthew R.

doi:10.1111/bju.13400

Search citation statements

Order By: Relevance

Paper Sections

Select...

Comparisons: Reported Unreported and Ongoing1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both trials contributed to the STOpCaP meta-analysis; aggregate data from 3206 patients with metastatic HNPC showed that docetaxel improved 4 year survival by 9% (hazard ratio 0.77; 95% confidence interval 0.68–0.87; P < 0.0001) [14] . These data have been practice changing [15] . The results of the ‘abiraterone comparison’ also show improved outcome; 3 year survival improved from 76% to 83%; hazard ratio 0.63 (95% confidence interval 0.52–0.76) [3] .…”

Section: Comparisons: Reported Unreported and Ongoingmentioning

confidence: 99%

Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform

et al. 2017

Self Cite

View full text Add to dashboard Cite

The treatment and outcomes for advanced prostate cancer have experienced significant progress over recent years. Importantly, the additional benefits of ‘up front’ chemotherapy (docetaxel) and abiraterone, over and above conventional androgen deprivation, have been separately demonstrated in the multi-arm, multi-stage (MAMS) STAMPEDE protocol, which continues recruitment to other questions. Alongside this, insights into the underlying molecular biology and, inevitably, the molecular heterogeneity of prostate cancer are opening the door to new therapeutic approaches. Incorporating this understanding and testing these hypotheses within STAMPEDE brings new challenges to the MAMS approach, but has the potential to further improve the outlook for this disease.

show abstract

Section: Comparisons: Reported Unreported and Ongoingmentioning

confidence: 99%